Scholarlink

Background <p>The fasting insulin to high-density lipoprotein cholesterol ratio (FINS/HDL-C) is a newly identified insulin resistance (IR) marker. And the correlation between FINS/HDL-C and metabolic dysfunction-associated steatotic liver disease (MASLD) has not yet been explored, our study investigated the association between FINS/HDL-C and MASLD severity.</p> Methods <p>This cross-sectional study included 330 participants with overweight/obesity and MASLD. Demographic information and biochemical indicators were collected, and IR markers including FINS/HDL-C, homeostatic model assessment for insulin resistance (HOMA-IR), triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C), and triglyceride glucose index (TyG), were calculated. MASLD severity was assessed using the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) determined by FibroScan. The relationship between FINS/HDL-C and MASLD severity was evaluated and compared with that of other IR markers.</p> Results <p>Participants with higher CAP and LSM exhibited significantly higher FINS/HDL-C (<i>P</i> &lt; 0.05). Even in the fully adjusted linear regression model, FINS/HDL-C remains positively correlated with CAP (β = 0.28, 95% CI 0.03 ~ 0.53, <i>P</i> = 0.030) and LSM (β = 1.71, 95% CI 0.33 ~ 3.09, <i>P</i> = 0.015). And FINS/HDL‑C was the only biomarker that showed elevated CAP at Quartile 2. Exploratory analysis suggested that BMI might be involved in the association between FINS/HDL-C and CAP and LSM. FINS/HDL-C had the highest area under the receiver operating characteristic curve for severe hepatic steatosis, at 0.699 (95% CI: 0.639 ~ 0.758).</p> Conclusions <p>Our findings suggest that FINS/HDL-C is associated with MASLD severity in overweight/obese individuals. It might serve as a valuable biomarker for MASLD risk stratification.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Fasting insulin to HDL-C ratio is correlated with MASLD severity in Chinese overweight/obesity: a cross-sectional analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月23日

查看全文
  • Xiaojuan Xu,
  • Xincheng Wang,
  • Lulu Yu,
  • Xiaotian Yang,
  • Peiyao Wang,
  • Yimeng Wang,
  • Zhenyang Guan,
  • Chunjun Li,
  • Tao Han

摘要

Background

The fasting insulin to high-density lipoprotein cholesterol ratio (FINS/HDL-C) is a newly identified insulin resistance (IR) marker. And the correlation between FINS/HDL-C and metabolic dysfunction-associated steatotic liver disease (MASLD) has not yet been explored, our study investigated the association between FINS/HDL-C and MASLD severity.

Methods

This cross-sectional study included 330 participants with overweight/obesity and MASLD. Demographic information and biochemical indicators were collected, and IR markers including FINS/HDL-C, homeostatic model assessment for insulin resistance (HOMA-IR), triglyceride to high-density lipoprotein cholesterol ratio (TG/HDL-C), and triglyceride glucose index (TyG), were calculated. MASLD severity was assessed using the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) determined by FibroScan. The relationship between FINS/HDL-C and MASLD severity was evaluated and compared with that of other IR markers.

Results

Participants with higher CAP and LSM exhibited significantly higher FINS/HDL-C (P < 0.05). Even in the fully adjusted linear regression model, FINS/HDL-C remains positively correlated with CAP (β = 0.28, 95% CI 0.03 ~ 0.53, P = 0.030) and LSM (β = 1.71, 95% CI 0.33 ~ 3.09, P = 0.015). And FINS/HDL‑C was the only biomarker that showed elevated CAP at Quartile 2. Exploratory analysis suggested that BMI might be involved in the association between FINS/HDL-C and CAP and LSM. FINS/HDL-C had the highest area under the receiver operating characteristic curve for severe hepatic steatosis, at 0.699 (95% CI: 0.639 ~ 0.758).

Conclusions

Our findings suggest that FINS/HDL-C is associated with MASLD severity in overweight/obese individuals. It might serve as a valuable biomarker for MASLD risk stratification.